Vcanbio Receives NMPA Approval for VUM02 Stem Cell Therapy in Liver Failure and ARDS
China-based Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) has announced receiving clinical trial...
Dizal Pharmaceutical Presents Updates on Sunvozertinib and Golidocitinib at ASCO 2023
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) presented updates on the clinical development of its...
Abbisko Therapeutics’ Pimicotinib Earns PRIME Status for TGCT from EMA
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced that its Category 1 drug...
NMPA Approves Shenzhen Core Medical’s Implantable Left Ventricular Assist System
The National Medical Products Administration (NMPA) has issued market approval for the implantable left ventricular...
uBriGene Partners with Everlife Biomed to Advance iPSC Therapy Preparation
China-based uBriGene, a leading cell and gene therapy contract development and manufacturing organization (CDMO), has...
EpimAb Biotherapeutics Appoints Dr. Zhu Yonghong as Chief Medical Officer
Shanghai-based biotech company EpimAb Biotherapeutics has announced the appointment of Dr. Zhu Yonghong to the...
CStone Pharmaceuticals and Servier Report Positive AGILE Study Results for Tibsovo at ASCO
CStone Pharmaceuticals’ (HKG: 2616) French partner, Servier, has published the latest results of the global...
BioNTech’s DB-1303 ADC Shows Promising Results in Solid Tumor Phase I/IIa Trial
Germany’s BioNTech (NASDAQ: BNTX) has released preliminary data from a Phase I/IIa trial for DB-1303,...
Gilead’s Kite Announces Breakthrough Phase III Results for Yescarta in r/r LBCL
Gilead’s (NASDAQ: GILD) subsidiary Kite has published groundbreaking Phase III results for Yescarta (axicabtagene ciloleucel),...
ITabMed Ltd Receives NMPA IND Approval for A-337, a CD3-Activating BsAb Targeting EpCAM
Shanghai-based biotech firm ITabMed Ltd has announced the receipt of Investigational New Drug (IND) approval...
China’s MOST Issues Updated HGR Rules Impacting Foreign Collaborations in Genetic Research
China’s Ministry of Science and Technology (MOST) has issued the “Detailed Implementation Rules for the...
Luye Pharma’s Lurbinectedin for Metastatic SCLC Accepted for Review by China’s NMPA
China-based Luye Pharma Group (HKG: 2186) has announced that its market filing for lurbinectedin (LY01017)...
Shanghai Runda Medical Science and Technology Partners with Huawei Cloud on AI in Healthcare
China-based Shanghai Runda Medical Science and Technology Co., Ltd (SHA: 603108) is set to collaborate...
Lee’s Pharmaceutical Subsidiary Zhaoke Ophthalmology Announces FDA Review of NVK002 for Pediatric Myopia
China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) subsidiary, Zhaoke Ophthalmology Ltd (HKG: 6622), has announced...
Legend Biotech Submits sBLA to Expand Carvykti Label for Relapsed Multiple Myeloma
Legend Biotech Corporation (NASDAQ: LEGN) has announced the submission of a supplemental Biologics License Application...
Zai Lab and Novocure’s TTFields Show Survival Benefit in NSCLC, Despite Stock Plunge
China-based Zai Lab Ltd (ZLAB) (NASDAQ: ZLAB; HKG: 9688) and its partner Novocure Ltd (NASDAQ:...
Shanghai Junshi Biosciences to List GDRs on Swiss Exchange, Raising RMB 3.4 Billion
China-based Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) is preparing to issue 68,292,200...
CStone Pharmaceuticals Presents Ayvakit Data for Advanced GIST at ASCO 2023
China-based CStone Pharmaceuticals (HKG: 2616) announced that new data from a post hoc analysis of...
Hansoh Pharmaceutical Gets NMPA Approval for HS-20117 Bispecific Antibody Clinical Study
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced receiving approval from the National...
Chinese Pharma Companies Update Pipelines at ASCO 2023 Annual Meeting
A number of Chinese pharmaceutical companies have shared updates on their pipeline developments at the...